Patient Characteristics, Persistence to Treatment and Outcome Events in Patients Treated With Ticagrelor 60 mg After Myocardial Infarction in Real-world Clinical Practice

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

7035 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-09-25

Study Completion Date

2021-06-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an observational study based on secondary data extracted from multiple register-based data sources in the US and Europe (Sweden, United Kingdom, Italy, Germany). The study will include patients initiating treatment with ticagrelor 60 mg after a myocardial infarction in real-world clinical practice, and describe their patient characteristics and duration of treatment. If the a priori threshold of 5,000 person-years on treatment with ticagrelor 60 mg is met, outcome events (bleeding and cardiovascular events) will also be analysed and described.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

NCT01225562

Myocardial Infarction Cardiovascular Death Atherothrombosis +1 more

COMPLETED PHASE3

Outcomes in UK ACS Patients Prescribed Ticagrelor

NCT03058601

Acute Coronary Syndrome

COMPLETED

A Study of Low and Standard-dose Ticagrelor After Intervention for ACS Patients

NCT04255602

Acute Coronary Syndrome Coronary Stent Implantation

UNKNOWN PHASE4

ADHerence of ticagrelOr in Real World Patients With aCute Coronary Syndrome

NCT03129867

Acute Coronary Syndrome

COMPLETED

Ticagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention

NCT04240834

Acute Coronary Syndrome Interventional Cardiology

RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This observational cohort study will include patients initiating treatment with ticagrelor 60 mg after a myocardial infarction (MI), and describe their patient characteristics and persistence to treatment. To contextualise the characteristics of the ticagrelor patients, two reference cohorts will be created, including patients treated with another P2Y12 inhibitor than ticagrelor (clopidogrel, prasugrel, or ticlopidine), and patients not treated with any P2Y12 inhibitor, within a comparable timepoint from an MI as for the ticagrelor 60 mg patients. If the a priori threshold of 5,000 person-years on treatment with ticagrelor 60 mg is met, to ensure sufficient precision, outcome events (bleeding and cardiovascular events) will also be analysed and described. Outcome events will only be described in the ticagrelor cohorts; no comparison of outcomes will be made between the ticagrelor and the reference cohorts.

The primary outcome is bleeding requiring hospitalisation. The secondary outcomes include components of the primary outcome, and cardiovascular outcomes. Persistence to treatment with ticagrelor 60 mg will also be assessed The study will be performed in the US and 4 European countries (Sweden, United Kingdom, Italy, Germany).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myocardial Infarction (MI)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ticagrelor cohort

Patients initiating ticagrelor 60 mg after an MI, with no prescription of ticagrelor 60 mg prior to their qualifying MI. The qualifying MI is defined as the most recent MI occurring before the first ticagrelor 60 mg prescription.

No interventions assigned to this group

Non-ticagrelor cohort

Patients not prescribed ticagrelor 60 mg at a comparable time point after an MI as matched patients in the ticagrelor cohort. Patients may be prescribed another P2Y12 inhibitor or aspirin alone.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Primary Analysis Population:

* Hospitalisation with a primary diagnosis of MI during the eligibility period
* Ticagrelor cohort: A first prescription of ticagrelor 60 mg after the most recent hospitalisation with a primary diagnosis of MI.
* Non-ticagrelor cohort: A prescription of clopidogrel, prasugrel or ticlopidine, or no prescription for any of these medications, at a comparable timepoint relative to their MI as for the ticagrelor cohort

Secondary Analysis Population:

* The qualifying prescription 12-36 months after a hospitalisation with a primary diagnosis of MI and treatment with an ADP receptor antagonist (clopidogrel, prasugrel, ticagrelor 90 mg, ticlopidine) ≤12 months prior to the qualifying prescription, or the qualifying prescription 12-24 months after a hospitalisation with a primary diagnosis of MI AND
* Age ≥50 years
* At least one of the following risk factors:

* Age ≥ 65 years
* Diabetes mellitus requiring medication
* A second prior MI
* Evidence of multivessel coronary artery disease
* Chronic non-end-stage renal dysfunction

Exclusion Criteria

Applicable to the Primary and Seconday Analysis Populations:

* Dies, emigrates, or disenrolls from the database (where applicable) prior to the ticagrelor approval date.
* Ineligibility for ticagrelor use (restricted to the conditions possible to capture within the data sources)-one or more of the following:

* Concomitant use of an anticoagulant
* Prior ischaemic stroke
* Prior history of intracranial bleeding
* Severe hepatic impairment
* Gastrointestinal bleeding
* Renal failure requiring dialysis
* Concomitant use of a strong CYP3A4 inhibitor or inducer
* \<1 year of data available prior to the qualifying MI (for assessment of patient characteristics at qualifying MI)

Maximum Eligible Age

130 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No